Trazodone and Sildenafil Interaction: What Patients and Prescribers Need to Know

Why Trazodone and Sildenafil Are Frequently Co-Prescribed

Trazodone and sildenafil often end up on the same prescription list for straightforward reasons. Trazodone is one of the most commonly prescribed off-label sleep aids in the United States, used at doses of 25-150 mg nightly. Sildenafil (Viagra, Revatio) is among the most frequently dispensed medications for erectile dysfunction, taken on demand at 25-100 mg.

The Patient Who Takes Both

The overlap population is larger than many clinicians expect. A man in his 50s or 60s with depression or insomnia may be on trazodone prescribed by his psychiatrist or primary-care physician. The same man may seek sildenafil from a telehealth platform or urologist. Neither provider always has full visibility into the other's prescriptions.

A 2021 analysis using the FDA Adverse Event Reporting System (FAERS) found that reports of hypotension co-listed trazodone and a PDE5 inhibitor more often than would be predicted by chance alone, though causality in FAERS reports cannot be established from spontaneous data alone [1]. The clinical interaction is real enough that the FDA prescribing information for sildenafil (Viagra) specifically warns about co-administration with drugs that have vasodilatory properties [2].

Trazodone's Primary Pharmacology

Trazodone belongs to the serotonin antagonist and reuptake inhibitor (SARI) class. At low doses used for insomnia, its dominant action is antagonism of histamine H1 and alpha-1 adrenergic receptors. That alpha-1 blockade is what produces orthostatic hypotension as one of trazodone's most common side effects. The FDA-approved trazodone label notes hypotension, including orthostatic hypotension and syncope, in roughly 5% of patients in key trials [3].

The Core Pharmacodynamic Interaction: Additive Hypotension

The most clinically pressing concern is not a drug-level pharmacokinetic interaction but a direct blood-pressure effect. Both trazodone and sildenafil lower blood pressure through independent mechanisms, and the effects add together.

How Each Drug Lowers Blood Pressure

Trazodone blocks alpha-1 adrenergic receptors on vascular smooth muscle. This reduces peripheral vascular resistance and venous return, particularly when patients move from lying to standing.

Sildenafil inhibits phosphodiesterase type 5 (PDE5), preventing the breakdown of cyclic GMP in vascular smooth muscle. Elevated cyclic GMP relaxes smooth muscle, dilating both arterial and venous beds. In a placebo-controlled pharmacodynamic study published in the Journal of the American College of Cardiology, sildenafil 100 mg reduced mean standing systolic blood pressure by approximately 8-9 mmHg in healthy volunteers [4].

Why the Combination Matters Clinically

When alpha-1 blockade (trazodone) and cyclic-GMP-mediated vasodilation (sildenafil) occur simultaneously, the blood-pressure drop is larger than either drug alone produces. The FDA label for sildenafil explicitly flags alpha-blockers as drugs requiring caution due to additive hypotensive effects, and the pharmacodynamic basis for that warning applies equally to trazodone's alpha-1 antagonism [2].

Patients taking antihypertensives on top of both drugs face an even steeper drop. A 2010 study in Hypertension confirmed that sildenafil in men already on antihypertensive therapy produced an additional 3-6 mmHg systolic reduction compared with men not on antihypertensives [5].

Recognizing Hypotensive Events

Clinical presentations range from mild lightheadedness when rising from bed (the most common scenario with trazodone taken at night and sildenafil taken earlier in the evening) to frank syncope. Both drugs tend to be taken in the evening hours, which concentrates their overlapping plasma peak times between roughly 1 and 4 hours post-dose.

Pharmacokinetic Interaction: Shared CYP3A4 Metabolism

Beyond the blood-pressure pharmacodynamics, trazodone and sildenafil share a metabolic pathway that can raise plasma levels of both compounds.

CYP3A4 and Trazodone

Trazodone is primarily metabolized by CYP3A4 to its active metabolite, meta-chlorophenylpiperazine (mCPP). A 2003 pharmacokinetic study in Drug Metabolism and Disposition showed that the CYP3A4 inhibitor ketoconazole increased trazodone AUC by approximately 52% and mCPP AUC by a smaller, offsetting margin [6]. MCPP has serotonergic and anxiogenic properties of its own, and elevated mCPP levels may contribute to side effects.

CYP3A4 and Sildenafil

Sildenafil is also cleared predominantly by CYP3A4, with CYP2C9 playing a minor secondary role. The FDA label states that potent CYP3A4 inhibitors such as ritonavir, ketoconazole, and erythromycin increase sildenafil AUC by 11-fold, 3.1-fold, and 2.7-fold, respectively [2].

How the Two Drugs Interact at the Enzyme Level

Trazodone is a CYP3A4 substrate, not a potent inhibitor, so it does not dramatically raise sildenafil concentrations through competitive inhibition. The risk at the enzyme level is therefore modest compared with, say, a macrolide antibiotic added to sildenafil. Still, in patients who are already slow CYP3A4 metabolizers by genotype, or who are taking even a mild CYP3A4 inhibitor such as fluconazole or grapefruit juice, adding trazodone and sildenafil together may tip plasma sildenafil concentrations higher than expected.

The table below summarizes the two interaction pathways side by side.

| Interaction Type | Mechanism | Magnitude | Clinical Result | |---|---|---|---| | Pharmacodynamic (BP) | Alpha-1 blockade (trazodone) + PDE5 inhibition (sildenafil) | Additive, ~8-15 mmHg systolic in at-risk patients | Orthostatic hypotension, dizziness, syncope | | Pharmacokinetic (CYP3A4) | Shared CYP3A4 substrate competition | Mild unless a third CYP3A4 inhibitor is present | Elevated sildenafil or trazodone exposure | | Pharmacodynamic (QT) | Both agents may prolong QTc | Additive; trazodone effect larger | Risk increases in hypokalemia, bradycardia | | Pharmacodynamic (priapism) | Both agents promote penile erection via separate pathways | Additive | Prolonged erection, priapism risk |

QT-Interval Prolongation Risk

Trazodone carries a well-documented QT-prolonging effect. A population pharmacokinetic-pharmacodynamic analysis published in Clinical Pharmacology and Therapeutics estimated that trazodone at therapeutic doses produces a mean QTc prolongation of approximately 7-10 ms [7]. Sildenafil's QT effect is smaller and generally considered clinically insignificant at standard doses, but published case reports describe QTc prolongation in the setting of sildenafil overdose or in patients with pre-existing cardiac conduction abnormalities.

Who Is Most at Risk for QT Events

Patients with baseline QTc >450 ms, hypokalemia, hypomagnesemia, or concurrent use of other QT-prolonging drugs (antipsychotics, certain antibiotics, methadone) face the greatest risk. The CredibleMeds/Arizona CERT database classifies trazodone in its "known risk" category for torsades de pointes [8].

Baseline ECG Recommendation

For patients on trazodone doses above 100 mg nightly who are also starting sildenafil, a baseline 12-lead ECG is a reasonable precaution. Any QTc >500 ms should prompt cardiology consultation before proceeding with the combination.

Priapism: A Separate but Additive Risk

Priapism is a painful, sustained erection lasting more than four hours that constitutes a urologic emergency. Both trazodone and sildenafil independently raise the risk.

Trazodone-Induced Priapism

Trazodone is one of the best-recognized drug causes of priapism. The proposed mechanism involves alpha-1 adrenergic blockade in the corpus cavernosum, which prevents detumescence. A review in Journal of Sexual Medicine estimated the incidence at approximately 1 in 6,000 male patients on trazodone, though the authors note underreporting is likely [9].

Sildenafil and Prolonged Erection

Sildenafil's PDE5 inhibition also sustains erection by keeping smooth muscle in the corpus cavernosum relaxed. At standard doses in men without sickle cell disease or anatomical risk factors, priapism is rare, but reported cases exist.

Combined Risk

No large prospective trial has quantified the priapism risk of the combination directly. Based on mechanism alone, co-prescribing both drugs in men with additional risk factors (sickle cell disease, leukemia, pelvic anatomical abnormalities) warrants explicit counseling: any erection lasting more than two to three hours requires immediate emergency evaluation.

Dose-Adjustment and Monitoring Guidance

Starting Sildenafil in a Patient Already on Trazodone

The recommended starting dose of sildenafil in patients on vasodilatory drugs is 25 mg, taken at least two hours before or after the trazodone dose if possible. The FDA label for sildenafil (Viagra) states: "Consider a starting dose of 25 mg in patients receiving concomitant alpha-blockers" [2]. Trazodone's alpha-1 blockade places it in a functionally similar category to prazosin or doxazosin for this purpose.

Temporal separation of the two doses reduces the window of overlapping peak plasma concentrations. Trazodone taken at 9 PM reaches peak plasma levels around 10-11 PM. Sildenafil taken at 7 PM (two hours prior) will be past its plasma peak by the time trazodone peaks, reducing simultaneous vasodilatory burden.

Starting Trazodone in a Patient Already on Sildenafil

Begin trazodone at 50 mg nightly and instruct patients to measure blood pressure sitting and standing on the first three mornings after each dose increase. A drop of more than 20 mmHg systolic or 10 mmHg diastolic on standing, accompanied by symptoms, warrants a dose reduction or switch to a non-vasodilatory sleep aid.

Blood Pressure Monitoring Protocol

• Measure supine and standing blood pressure at baseline before combining the drugs.
• Recheck after the first week of combination use.
• Instruct patients to rise slowly from bed, sit at the bedside for 60 seconds before standing, and avoid combination use after alcohol consumption (ethanol independently lowers blood pressure and prolongs sildenafil's hypotensive effect).

Alcohol as an Amplifier

A study in Clinical Pharmacology and Therapeutics showed that moderate alcohol consumption (0.5 g/kg) combined with sildenafil 25 mg produced additional mean systolic blood pressure drops of 7 mmHg compared with sildenafil alone [10]. Adding trazodone's alpha-1 blockade to that milieu is a three-way additive event.

Special Populations

Older Men (Age >65)

Older adults have reduced alpha-1 adrenergic receptor reserve, slower CYP3A4 clearance, and higher baseline rates of orthostatic hypotension. The sildenafil label recommends a starting dose of 25 mg in men aged >65, independent of drug interactions [2]. The combination of age and trazodone co-prescription should prompt the prescriber to cap sildenafil at 25-50 mg and revisit fall-risk assessment.

Patients on Antihypertensives

This is the highest-risk subgroup. Triple vasodilation (antihypertensive + trazodone + sildenafil) can produce clinically significant hypotension even at low doses. If sildenafil is considered necessary in this group, the prescriber should evaluate whether the antihypertensive dose can be reduced or whether trazodone can be switched to a non-vasodilatory sleep aid such as low-dose doxepin (3-6 mg, FDA-approved for insomnia) or ramelteon.

Patients with Cardiac Disease

Sildenafil is contraindicated with nitrates and nitric oxide donors. Trazodone does not carry a nitrate contraindication independently. However, patients with cardiac disease who are on nitrates should not receive sildenafil regardless of trazodone status, and trazodone's QT-prolonging effect may require additional cardiac monitoring.

Patient Counseling Points

Clear patient-level communication reduces adverse-event risk. The conversation should cover at minimum:

• Take sildenafil two or more hours before the trazodone bedtime dose, not after.
• Rise slowly from any recumbent position. Sit at the edge of the bed for at least 60 seconds before standing.
• Avoid alcohol on any night both drugs are taken.
• Stop sexual activity and seek care immediately for chest pain, severe dizziness, or sudden vision changes.
• Seek emergency care for any erection lasting more than two to three hours. Do not wait four hours.
• Keep a blood pressure log for the first two weeks of combination use.

When to Avoid the Combination Entirely

Prescribers should reconsider the combination, or substitute one agent, in the following scenarios:

• Baseline QTc >500 ms or history of torsades de pointes
• Current use of a nitrate (absolute contraindication to sildenafil, independent of trazodone)
• Three or more concurrent antihypertensives with documented orthostatic hypotension
• History of priapism on either drug alone
• Sickle cell disease or other conditions predisposing to priapism
• Severe hepatic impairment (reduces clearance of both drugs via CYP3A4)

In most of these situations, an alternative sleep aid (ramelteon, low-dose doxepin, or melatonin) pairs more safely with sildenafil than trazodone does.

Summary of Interaction Severity Ratings Across Major Databases

Different clinical databases classify this combination differently, which reflects genuine uncertainty about magnitude rather than disagreement about mechanism.

• Micromedex (IBM): Moderate severity, reasonable to use with monitoring
• Drugs.com Interaction Checker: Moderate; monitor for hypotension
• Clinical Pharmacology (Elsevier): Moderate; dose-adjust and counsel
• CredibleMeds: Trazodone listed as "known risk" for QT; sildenafil as "conditional risk"

None of these sources classifies the combination as absolutely contraindicated, provided appropriate dose adjustment and monitoring are in place.